<DOC>
	<DOCNO>NCT01354353</DOCNO>
	<brief_summary>This inpatient , open-label , multiple-dose , multicenter study evaluate safety tolerability LY2140023 give dos expect reflect multiple anticipate therapeutic exposure clinical investigation . In event poor tolerability part A study part B may conduct explore high dos use titration . Subjects part A B participate 9 day wash-out period current medication ( Study day 1-9 ) ; subject come study aripiprazole remain current therapy throughout .</brief_summary>
	<brief_title>A Study Safety Tolerability Subjects With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Have diagnosis schizophrenic disorder Female subject test negative pregnancy screen agree use reliable method birth control duration study least 3 month last LY2140023 dose postmenopausal Not hospitalize psychiatric illness least 12 week prior Day 1 washout period CGIS score &lt; 4 Be willing able determine investigator hospitalize begin washout period end study In opinion investigator , subject wash Standard Care ( SOC ) therapy ( aripiprazole aripiprazole subject ) duration study without detrimental effect subject 's mental health ( Clinical Global ImpressionSeverity Scale ( CGIS ) &lt; 4 completion washout period ) Be consider reliable , level understanding sufficient perform test examination require protocol , willing perform study procedure Be able understand nature study give informed consent Have clinical laboratory test result within normal reference range population investigator site , result acceptable deviation judge clinically significant investigator Have venous access sufficient allow blood sample Clinically acceptable sit blood pressure pulse rate , determine investigator Subjects Aripiprazole prior study entry must : On stable dose aripiprazole within approved range product labeling ( less equal 30 mg/day ) least 60 day prior Day 1 anticipation change dose , regimen ( except require study ) treatment within next 1 month Currently enrol , discontinue within 30 day prior screen , clinical trial involve investigational drug concurrently enrol type medical research judge scientifically medically compatible study Have know allergy LY2140023 , LY404039 , aripiprazole , related compound Subjects moderate severe renal impairment define creatinine clearance ( CrCl ) &lt; 60 ml/min Have previously complete study discontinue study investigate LY2140023 receive least 1 dose LY2140023 Subjects treatment LY2140023 aripiprazole specify protocol , relatively absolutely clinically contraindicated Subjects receive treatment clozapine Subjects diagnosis schizophrenia take either thioridazine thiothixene Subjects receive treatment depot antipsychotic medication within 12 week , prior screen Subjects take medication specifically exclude Subjects answered 'yes ' either Question 4 ( Active Suicidal Ideation Some Intent Act , Without Specific Plan ) Question 5 ( Active Suicidal Ideation Specific Plan Intent ) `` Suicidal Ideation '' portion Columbia suicide severity rating scale ( CSSRS ) , answer `` yes '' suiciderelated behavior ( actual attempt , interrupt attempt , abort attempt , preparatory act behavior ) `` Suicidal Behavior '' portion CSSRS ; ideation behavior occur within past 3 month Diagnostic Statistical Manual Mental DisordersFourth Edition ( Text Revision ) ( DSMIVTR ) diagnosis substance dependence substance abuse ( except nicotine caffeine ) within 6 month prior admission Diagnosis substanceinduced psychosis DSMIVTR criterion within 7 day admission ( time dose period ) Have history one seizures except either follow 2 situation : single simple febrile seizure age 6 month 5 year single seizure identifiable etiology , completely resolve Have screen electroencephalogram ( EEG ) paroxysmal ( epileptiform ) activity , example , one demonstrate 3 focal sharp spike wave , sharp slow wave complex , epileptiform discharge rhythmic , sustain , generalize , locally define Subjects electroconvulsive therapy ( ECT ) within 3 month observation period expect ECT time live phase study A diagnosis Parkinson 's disease , dementiarelated psychosis , related disorder Subject untreated hyperthyroidism hypothyroidism need thyroid hormone supplement stable dose medication least 2 month prior screen Have leukopenia history leukopenia subject 's lifetime Subjects alanine aminotransferase ( ALT/SGPT ) aspartate aminotransferase ( AST/SGOT ) value &gt; 2 time upper limit normal ( ULN ) perform laboratory , total bilirubin value &gt; 1.5 time ULN perform laboratory screen Subjects correct QT interval ( Bazett 's ) ; QTcB ) &gt; 450 msec ( male ) &gt; 470 msec ( female ) admission Have acute , serious unstable medical condition , include ( limited ) inadequately control diabetes ( hemoglobin A1c ( HgbAlc ) &gt; 8 % ) , severe hypertriglyceridemia ( fast triglyceride great equal 500 mg/dL 5.65 mmol/L ) , hepatic insufficiency ( specifically degree jaundice ) , recent cerebrovascular accident , seizure disorder , serious acute systemic infection immunology disease , unstable cardiovascular disorder ( include ischemic heart disease ) , renal , gastroenterologic , respiratory , endocrinologic , neurologic , hematologic disease Prolactin level &gt; 200 ng/mL ( 200 ug/L , 4228 mIU/L ) screen exception subject treat risperidone . Subjects treat risperidone exclude prolactin level &gt; 300 ng/mL ( 300 ug/L , 6342 mIU/L ) screening ) Subjects known medical history Human Immunodeficiency Virus positive ( HIV+ ) status Test positive ( 1 ) Hepatitis C virus antibody ( 2 ) Hepatitis B surface antigen ( HBsAg ) without positive Hepatitis B core total antibody . Subjects positive Hepatitis B core antibody test negative HBsAg may include study ALT/SGPT AST/SGOT level less 2 time upper limit normal ( ULN ) total bilirubin exceed ULN central laboratory</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>